U.S. markets closed
  • S&P 500

    3,819.72
    -50.57 (-1.31%)
     
  • Dow 30

    31,270.09
    -121.43 (-0.39%)
     
  • Nasdaq

    12,997.75
    -361.04 (-2.70%)
     
  • Russell 2000

    2,207.79
    -23.72 (-1.06%)
     
  • Crude Oil

    61.13
    +1.38 (+2.31%)
     
  • Gold

    1,711.40
    -22.20 (-1.28%)
     
  • Silver

    26.22
    -0.66 (-2.45%)
     
  • EUR/USD

    1.2067
    -0.0020 (-0.17%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • GBP/USD

    1.3951
    -0.0006 (-0.04%)
     
  • USD/JPY

    107.0100
    +0.3000 (+0.28%)
     
  • BTC-USD

    50,999.46
    +3,498.72 (+7.37%)
     
  • CMC Crypto 200

    1,020.73
    +32.64 (+3.30%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Recap: Jazz Pharmaceuticals Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) were flat in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 9.50% year over year to $4.00, which missed the estimate of $4.20.

Revenue of $665,517,000 higher by 14.40% year over year, which beat the estimate of $639,550,000.

Outlook

Jazz Pharma Sees FY21 Sales $2.55B-$2.7B vs $2.56B Estimate, Adj. EPS $15.65-$16.85 vs $16.78 Estimate

Conference Call Details

Date: Feb 23, 2021

Time: 04:30 PM

View more earnings on JAZZ

ET Webcast URL: https://edge.media-server.com/mmc/p/7h5iem3y

Price Action

52-week high: $172.67

Company's 52-week low was at $86.88

Price action over last quarter: Up 5.93%

Company Description

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.